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Economic evaluation involves the comparative analysis of the
costs and consequences of alternative programmes or
interventions.
1 It has increasingly been used to inform decision
making about healthcare in the United Kingdom and other
industrialised nations.
2-5 Randomised controlled trials are
commonly used as a vehicle for economic evaluations. Indeed,
many funders, such as the UK National Institute for Health
ResearchHealthTechnologyAssessmentProgramme,routinely
request that assessments of cost effectiveness are incorporated
in the design of randomised trials. This article outlines some of
the key issues concerning the design, conduct, analysis, and
reportingofeconomicevaluationsbasedontrialswithindividual
patient data. Economic evaluations that synthesise data from
disparate sources using decision analytical models (typically
usingsummaryratherthanindividualpatientdata)arediscussed
in an accompanying article.
6
What are the objectives of economic
evaluation?
Economic evaluations are typically concerned with two
quantities:theadditionalcostofanewtreatmentcomparedwith
the existing alternative and the additional health benefits. If all
the costs and outcomes relevant to this comparison can be
measured, they can then be averaged across all patients in the
treatment (t) or the control (c) group to obtain mean cost C and
mean effect E for each group. It then becomes possible to
calculate a third quantity: the cost effectiveness of the new
treatment compared with the alternative. The incremental cost
effectivenessratio(ICER)willsimplybethedifferenceincosts
dividedbythedifferenceineffects:ICER=Ct−Cc/Et−Ec=ΔC/ΔE.
Thiscanbeshownneatlyonthecosteffectivenessplane(fig⇓).
7
In the south east quadrant of the figure⇓ the new intervention
is less costly and more effective and (assuming there is no
uncertainty surrounding the cost effectiveness ratio) should be
adopted; equally, if the new intervention is less effective and
morecostly(thenorthwestquadrant),itcanreadilyberejected.
Morecontroversially,newinterventionsmayturnouttobemore
effective but also more costly (north east quadrant) or less
effective but also less costly (south west quadrant): in either
case, a trade-off then exists between effect and cost: additional
health benefit can be obtained but at higher cost, or costs can
be saved but only by giving up health benefit.
The question that then arises is whether the trade-off is
acceptable: is the health gain (or cost saving) worth the
additional cost (or health loss)? To address this question, we
can imagine a diagonal line running through the figure⇓
depictingthemaximumwearewillingtopayforaunitofeffect
(sometimes represented by the Greek letter λ). All points to the
right of this line involve a trade-off between costs and health
benefitsthatadecisionmakermightconsideracceptable;while
all points to the left require an unacceptable trade-off. The
steepertheslopeofthisdiagonalline,themoredecisionmakers
are willing to pay for a unit of effect. There are various
techniques for estimating the value of λ.
8 In many jurisdictions,
however,ithastendedtoreflectexternallydetermineddecision
rules that have evolved historically and with little scientific
basis.
9 10 The point to note is that economic evaluation involves
two large uncertainties: where an intervention is located on the
cost effectiveness plane, and how much a decision maker is
willing to pay for health gains. Here we focus on the first
question, and consider the use of trial based economic
evaluations to obtain precise estimates of incremental cost
effectiveness.
Design of trial based economic
evaluations
Designing a rigorous trial based economic evaluation requires
closecollaborationbetweentrialistsandhealtheconomists.This
collaboration should be reflected in the standard operating
procedures of the coordinating clinical trials unit, including its
data collection and informed consent procedures.
11 Where
possible, the instruments and procedures used to collect
economic data should be pilot tested for efficiency, clarity, and
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12 Pragmatic trials offer analysts an opportunity to
evaluate the cost effectiveness of an intervention under real
worldconditions,withenrolledpatientsrepresentativeoftypical
clinical caseloads, a comparison of the intervention of interest
with current practice, and follow-up under routine conditions.
1
With less naturalistic trial designs, such as explanatory trials
designed primarily to answer questions about safety and
efficacy, the generalisability of the economic evaluation may
be impaired by stringent inclusion criteria and treatment
protocols or by the absence of a “usual care” arm.
12 13 These
limitationsarehardtoovercome,althoughprotocoldrivencosts
can and should be factored out of cost effectiveness
calculations.
14
Although several techniques have been proposed to estimate
the appropriate sample size and statistical power for economic
endpointsinrandomisedtrials,
15-17powercalculationsarealmost
invariably based on primary clinical outcomes. This is partly
becauseofthecomplexityoftryingtoforecastthemainoutcome
ofinteresttoeconomists—thejointdistributionofthedifference
incostsandbenefitsbetweentreatmentarms.Furthermore,large
sample sizes may be needed to detect statistically significant
differences because of the large variability in use of healthcare
resources and cost measures,
18 and this may be neither
financiallynorethicallyacceptable.
1Economiststhereforefocus
on estimating cost and effect differences and assessing the
likelihood that an intervention is cost effective, rather than
testing a particular hypothesis concerning cost effectiveness.
18
Some people might wonder whether an economic evaluation
should be included in a trial before we know whether the new
treatment is more effective. However, if it is not included we
risk losing the opportunity to collect information on use of
resources and health related quality of life. Furthermore, as
noted above, cost effectiveness is about the joint distribution of
differencesincostandeffect.Thisjointdistributioncouldshow
clearcosteffectivenesswhenneithercostnoreffectdifferences
are individually significant. Indeed, some economists have
argued that reliance on traditional rules of statistical inference
surrounding a single parameter, such as clinical effectiveness,
is arbitrary and may result in inferior healthcare outcomes
comparedwithdecisionsbasedonexpectedcosteffectiveness.
1 19
How are data measured and valued?
Use of resources
The resources used by patients, such as hospital admissions,
consultations, and types and quantities of drugs administered,
are normally recorded for each patient over the trial follow-up.
The categories of resource use that are included in the study
will be determined by the perspective of the analysis—whether
it is confined to the healthcare system (sometimes referred to
as the payer) or includes broader societal costs. The system
perspective would typically include direct medical care,
including the intervention itself, treatment of any side effects
or complications, and follow-up care to the intervention or the
underlying condition. It may also include medical care not
directly associated with the underlying condition, although
regressionmodellingmayberequiredtodisentanglebackground
noise that often occurs when this is included.
20 In England and
Wales,theNationalInstituteforHealthandClinicalExcellence
(NICE)recommendsincludingNHSandpersonalsocialservices
as a minimum.
2The societal perspective also considers care
provided by other sectors of the economy, costs incurred by
patients, informal care provided by family and friends, and
productivity losses from morbidity and premature death.
Use of many resources can normally be recorded on trial case
report forms with little or no extra burden, but sometimes
additional information will be required from medical records,
patient questionnaires and diaries, and other sources.
21 A recent
trial based economic evaluation of neonatal extracorporeal
membraneoxygenationusedobservationalresearchtoestimate
resource use associated with complications and parental
questionnaires to document use of hospital and community
health services after discharge.
22 Computerised record linkage
mayinfuturesimplifytheprocessofcollectingtheseadditional
data.
Whendataarecollectedthroughpatientorcarerquestionnaires,
researchers have to balance recall bias against completeness of
sampling information.
23 Shorter recall periods of a few days or
weeks reduce the chance of a patient forgetting an episode or
incorrectly recalling when it occurred, but if a study is trying
toestimateresourceuseoveralongerperiod,suchas12months,
sampling over a short recall period misses lots of data. It may
be better to maximise completeness at the cost of some recall
bias.
24
Valuation of resource use
The total cost for an individual patient participating in a trial is
the product of the quantity of each resource item they use and
the unit cost of each item. Unit costs should theoretically be
based on the economic notion of opportunity cost, which
represents the value of the resource in its most highly valued
alternative use.
1 In practice this is usually assumed to be
approximated by nationally representative healthcare tariffs,
such as the NHS payment by results tariffs
25 or the diagnosis
relatedgrouppaymentsintheUSMedicaresystem.
26However,
unit costs are not always readily available from such sources
andmayhavetobecalculatedusingacombinationofaccounting
data, time and motion studies, interviews with caregivers, and
case note analysis.
Standardunitcostsareoftenappliedacrossallpatientsandtrial
centres, but non-standardised unit costs may be appropriate if
the relative prices of factors such as labour and equipment vary
between trial centres, especially in multinational trials.
27 28 All
costs should be valued at the same price date, with adjustment
using healthcare specific inflation indices when necessary.
29
Economic evaluations based on multinational trials should
convert costs into a common currency by using purchasing
power parity adjustments.
30
Measurement and valuation of outcomes
Cost effectiveness may be reported in terms of many different
outcome measures, ranging from biomedical markers to more
final health outcomes.
12 The preferred outcome measure for
many health economists, and many reimbursement agencies,
remains the quality adjusted life year (QALY), a preference
based measure of health outcome that combines length of life
andhealthrelatedqualityoflife.
31Forreimbursementagencies,
the QALY has the advantage of allowing cost effectiveness
comparisons between interventions for disparate health
conditions. For economists, the QALY offers the additional
advantage that it incorporates individual preferences for health
outcomes,therebymovingbeyondthenarrowbiomedicalmodel
for evaluative research.
To estimate QALYs patients typically complete at different
time points a generic health related quality of life questionnaire
with pre-existing preference weights that can be attached to
each health state—for example EQ-5D,
32 the Health Utilities
Index,
33 and the SF-6D.
34 The underpinning preference weights
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general population, and so descriptive data from patients are
combined with health related quality of life weights (or utility
scores) from the general population and survival data from the
trial to generate QALY profiles. An alternative approach is to
ask patients not only to describe their health status but also to
value it using a complex scaling technique such as the standard
gambleapproachortimetrade-offapproach.
35Thesetechniques
are more expensive and time consuming than using population
weighting. For both approaches, the frequency and timing of
assessments should be influenced by disease severity, speed of
progression, and the questionnaire burden on patients.
36 When
patients are too ill or do not have the cognitive competencies
to complete a questionnaire, proxy measurements may be
considered.
37
If a trial has not included a quality of life assessment, mapping
techniques can sometimes be used to predict preference based
healthrelatedqualityoflife(orutility)scoresbasedonresponses
to non-preference based measures.
38 This requires data from a
separate study where both the preference based and
non-preference based measures were completed. For example,
Williamson and colleagues used data from a study that
developed a utility algorithm for the OM8-30 otitis media with
effusionquestionnaire
39topredictpreferencebasedhealthrelated
quality of life scores, and consequently QALYs, for children
participating in a randomised trial of topical intranasal
corticosteroids for persistent bilateral otitis media with
effusion.
40
The QALY may be considered too restrictive or insensitive to
the main outcomes of interest in some circumstances.
Researchers are therefore developing instruments that try to
measure broader outcomes such as attachment, security,
enjoyment, role, and control that can still be used within an
economic evaluation framework.
41
Analysis and reporting of data
Discounting
Trialbasedeconomicevaluationsoftenmeasureandvaluecosts
and outcomes over several years of patient follow-up. In this
situation costs and outcomes that occur after the first year of
follow-uparetypicallyreducedbyadiscountfactorsothatthey
can be fairly compared. Some economists have argued for
applying different discount rates to future costs and health
outcomes,
42 but NICE recommends that economic evaluations
conducted in England and Wales should discount both costs
and outcomes at an annual rate of 3.5%.
2 Sensitivity analyses
that test the effects of differential discount rates on costs and
outcomes are recommended.
2
Dealing with skewed, missing, and censored
data
The costs and outcomes of the trial groups, and the respective
differences between them, can be summarised in several ways.
For costs, the crucial information is usually the arithmetic
mean—that is, average cost—as this allows policy makers to
estimate the total cost of implementing a programme or
intervention.
43Althoughcostdataareoftenrightskewedbecause
a few patients use very high amounts of resource, producing a
distribution that may violate the assumptions of standard
statistical tests, it is not clear that the many alternative
approaches suggested, such as bootstrapping, provide more
reliable test results.
44 Indeed, simple approaches for analysing
cost data that assume normal distributions may be preferable in
large samples where the near-normality of sample means is
assured,whilerelativelysimpleapproaches,suchasgeneralised
linearmodels,maybesufficientinsmallersamplestodealwith
problems such as skewness and excess zeros.
44 For clinical
outcomes, it is generally most transparent to replicate the
methods of the primary clinical analysis plan to summarise
outcomes. Note, however, that economists will be interested in
all events, whereas trialists may be more interested in time to
the first event. For QALYs, it may be important to adjust for
baseline differences in health status between the trial groups.
45
Missing data are a particular problem for economic evaluations
alongside trials, as the analysis may be drawing on information
from case report forms, adverse event data, medication files,
health related quality of life and resource use questionnaires,
and other sources at all points across the study. The problem
may be mitigated, in part, by approaches such as postal or
telephone reminders to patients. Nevertheless, a complete case
approach might require that most patients are dropped and is
seldom a realistic option. Instead, analysts increasingly favour
multiple imputation, where multivariate regression techniques
areusedtopredictmissingvaluesonthebasisofexistingdata.
46
The precise approach will depend on the nature of the missing
data: (i) missing completely at random, with no relation to the
value of any other factors in the study population; (ii) missing
at random, but correlated in an observable way with the
mechanism that generates the outcome; and (iii) not missing at
random, but dependent on unobserved variables.
46 A particular
form of missing data is censoring, where information on some
patients is truncated and not available for the full duration of
interest. In the past, analysts often ignored the effects of
censoring on the estimation of costs and outcomes, but survival
analysis methods are increasingly being used to deal with this
problem.
8
Handling uncertainty
As we noted when discussing the cost effectiveness plane, trial
based economic evaluations result in different types of
uncertainty. Sampling (or stochastic) uncertainty, usually
reported as a confidence interval, depends on variation in both
the numerator (incremental cost) and the denominator
(incrementaleffectiveness)oftheincrementalcosteffectiveness
ratio. However, ratios are difficult statistics to work with: in
costeffectivenessratiosthedenominator(theeffectdifference)
may be zero, producing an intractable result. Another problem
is that the same negative value might represent improved
outcomes and lower costs or worse outcomes and higher costs.
This makes confidence intervals hard to compute and to
interpret.
Analternativeistoassumethatthedecisionmaker’swillingness
to pay for health gain is known and then rearrange the ratio on
a linear scale to see whether the intervention produces any net
benefit. For example, if the actual health benefits produced by
the intervention are multiplied by the assumed willingness to
pay for these benefits, and the net costs are subtracted, we
produce a linear scale where a negative is unambiguously bad
(the costs outweigh the value placed on the health benefits) and
larger benefits are unambiguously better.
47 This net benefit
approach makes it straightforward to examine decision
uncertainty—that is, uncertainty over the value of the
willingness to pay for health gain (λ)—by assessing the
probability that the new intervention is cost effective across a
range of values of λ. This is often displayed as a cost
effectiveness acceptability curve.
48
Heterogeneity in the trial population could also be explored by
formulating a net benefit value for each patient from the
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modelwithatreatmentvariableandcovariatessuchasage,sex,
and disease severity. The magnitude and significance of the
coefficients on the interaction between the covariates and the
treatment variable might then provide an estimate of cost
effectivenessbysubgroup.Finally,methodologicaluncertainty,
the uncertainty concerning issues such as the appropriate
discount rate or cost perspective, can be explored by standard
sensitivity analyses.
Longer term extrapolation
Cost effectiveness observed within a trial may be substantially
different from what would have been observed with continued
patient follow-up: for example, the benefits of reducing fatal
outcomes typically continue well beyond the end of the trial.
Consequently, extrapolation of cost effectiveness over an
extended period, often a lifetime, is considered important.
36 49
Survival analysis models, such as the Cox proportional hazard
model or Weibull model, are often used to estimate life
expectancy with and without an intervention.
50 However,
unbiasedestimationoflongtermcosteffectivenessmayrequire
more complex models of the disease process, accompanied by
related information on the cost and utility of interventions and
complications.
Trial based economic evaluations that use patient level data
have important advantages in permitting the construction of
such models and permitting them to be validated. A good
examplecomesfromtheUKProspectiveDiabetesStudy.
51The
trial followed up patients for a median of 10 years. However,
the wealth of individual patient data permitted the construction
of a model consisting of a set of linked equations that predict
the risks of major diabetes related complications, and this has
been used to estimate the lifetime costs, utilities, and cost
effectivenessofdiabetesrelatedinterventions.
52Theinteractions
withinthemodelbetweenriskfactors,individualcharacteristics,
and disease history could not have been captured reliably
without access to patient level data.
Advantages of trial based economic
evaluations?
Economic evaluations conducted alongside randomised
controlledtrialsprovideanearlyopportunitytoproducereliable
estimates of cost effectiveness at low marginal cost. Access to
individual patient data also permits a wide range of statistical
and econometric techniques—for example, to examine the
relation between events of interest and health related quality of
life or to explore subgroup differences. Although trial based
evaluations have limitations—truncated time horizons, limited
comparators, restricted generalisability to different settings or
countries, and the failure to incorporate all relevant
evidence
53—they are likely to continue to have an important
role in producing reliable estimates of cost effectiveness.
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The cost effectiveness plane. The x axis shows the difference in effectiveness between the new treatment and the comparator
and the y axis shows the difference in cost. The slope of the line from any point on the figure to the origin is the incremental
cost effectiveness ratio
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;342:d1548 doi: 10.1136/bmj.d1548 (Published 7 April 2011) Page 6 of 6
RESEARCH METHODS & REPORTING